A practical reference on visceral adipose tissue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Intermittent pain/discomfort or swelling above the anus or near the tailbone Opaque yellow (purulent) or bloody discharge from the tailbone area Unexpected moisture in the tailbone region Discomfort sitting on the tailbone, doing sit-ups, or riding a bicycle—any activities that roll over the tailbone area Some people with a pilonidal cyst will be asymptomatic.
== Tumor cells and haptotaxis == A characteristic of many cancers is the ability to move throughout the body. These are malignant cells, and pose a serious threat to the health of an individual. It has been indicated that haptotaxis plays a role in the ability of malignant cells to metastasize. One factor that was initially found to influence haptotaxis is serum spreading factor, which is present in blood serum and interstitial tissues. The presence of serum spreading factor was shown to influence directed migration along a gradient of substrate molecules in a few types of cancer cells. Another component important in the haptotaxis of tumor cells is MenaINV, which is an actin regulatory protein that becomes increasingly expressed in tumor cells. This actin regulatory protein binds to fibronectin receptors and aids in the haptotactic and chemotactic processes of tumor cells.
Vaccinations will begin in March in Scotland, early April in England and Wales, and mid-April in Northern Ireland. RMT staff working for Network Rail call off a strike planned for 16 March after being given a fresh pay offer. 8 March The UK experiences its coldest March night since 2010, with −15.2 °C recorded in Kinbrace, Scotland, dipping even further to −15.4 °C by the morning. The Health Security Agency issues a level 3 cold alert for the whole of England, while more than 100 schools across Wales are closed due to snow. The National Institute for Health and Care Excellence (NICE) approves the use of the weight loss drug semaglutide (marketed as Wegovy) by the NHS in England. 9 March The UK government announces a two-year delay in the construction of the Birmingham to Crewe leg of HS2 in order to save costs. Asda and Morrisons lift their restrictions on the sale of fresh produce. Following a trial at the High Court in Aberdeen, retired research scientist Christopher Harrison, 82, is convicted of the murder of his ex-wife, Brenda Page, in 1978. 10 March The UK economy grew by 0.3% in January 2023, official figures show, much more than the 0.1% that was predicted by economists. The King bestows the title of Duke of Edinburgh on his younger brother, Prince Edward. Prime Minister Rishi Sunak attends a summit in Paris with French president Emmanuel Macron and announces the UK will give France £500m over three years to help the UK stop the influx of migrants arriving by boat.
John Scott Award, created in 1816 as the John Scott Legacy Medal and Premium, is presented to people whose inventions are deemed to have improved the "comfort, welfare, and happiness of human kind" in a significant way. Since 1919 the Board of Directors of City Trusts of Philadelphia provide this award, recommended by an advisory committee.
Sources: en.wikipedia.org
== Terminology == There exists some controversy about what structures are considered "fascia" and how they should be classified. The current version of the International Federation of Associations of Anatomists divides into:
The trend of serum creatinine concentrations over time is more important than the absolute creatinine concentration. Serum creatinine concentrations may increase when an ACE inhibitor (ACEI) is taken for heart failure and chronic kidney disease. ACE inhibitors provide survival benefits for patients with heart failure and slow disease progression in patients with chronic kidney disease. An increase not exceeding 30% is to be expected with use of an ACE inhibitor. Therefore, an ACE inhibitor should not be withdrawn when the serum creatinine increases, unless the increase exceeds 30% or hyperkalemia develops.
=== Other uses === Research into fungal dressings for the treatment of ulcers, and bed sores, using fungal mycelial filaments, is ongoing. In the past, slices of A. campestris were applied to scalds and burns in parts of Scotland.
Sources: en.wikipedia.org
=== Streptavidin gel-shift === Extent of biotinylation can also be measured by streptavidin gel-shift, since streptavidin remains bound to biotin during agarose gel electrophoresis or polyacrylamide gel electrophoresis. The proportion of target biotinylated can be measured via the change in band intensity of the target with or without excess streptavidin, seen quickly and quantitatively for biotinylated proteins by Coomassie brilliant blue staining.
=== 17 December === Missiles were launched targeting infrastructure on Kyiv, Kharkiv, Kryvyi Rih and Zaporizhzhia. Kyiv council member Ksenia Semenova stated that approximately 60% of residents were without power and 70% were without water. Ukraine restored power and water to approximately 6 million residents in 24 hours. 37 out of the 40 missiles fired at Kyiv were intercepted. Russia started a new campaign on TV to recruit more soldiers. One advertisement showed some men leaving for Georgia. An old woman drops her groceries and men who have not left help her pick them up. She then says: "The boys have left, the men stayed."
Anticoagulation Clinic Diabetes Education Dietary Services Emergency Department Care Home Health Services Laboratory Services Maternity Services Medical Education Pastoral Care Pediatric Services Radiology Rehabilitation Respiratory Senior Behavioral Medicine Care Sleep Diagnostic Services Speech and Hearing Services Surgical Services
== Reception == WHO director-general Tedros Adhanom, who was not directly involved with the investigation, said he was ready to dispatch additional missions involving specialist experts and that further research was required. He said in a statement, "Some explanations may be more probable than others, but for now all possibilities remain on the table". He also said, "We have not yet found the source of the virus, and we must continue to follow the science and leave no stone unturned as we do." Tedros also called on China to provide "more timely and comprehensive data sharing" as part of future investigations. News outlets noted that though it was unrealistic to expect quick and huge results from the report, it "offered few clear-cut conclusions regarding the start of the pandemic", "failed to audit the Chinese official position at some parts of the report", and was "biased according to critics". Other scientists praised how the report details the pathways that can shed light on the origin, if explored later. After the publication of the report, politicians, talk show hosts, journalists, and some scientists advanced unsupported claims that SARS-CoV-2 may have come from the WIV. In the United States, calls to investigate a laboratory leak reached a "fever pitch", fueling aggressive rhetoric resulting in antipathy towards people of Asian ancestry, and the bullying of scientists. The United States, European Union, and 13 other countries criticised the WHO-convened study, calling for transparency from China and access to the raw data and original samples.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.